foxo4 dri senolytic peptide human trial 2024 2025 The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI Peptide inhibitors targeting FOXO4-p53 interactions
Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI 10mg vial Description RCpeptides foxo4 dri senolytic peptide human trial 2024 2025 regulates endothelial cell senescence via the P53 signaling pathway FOXO4 DRI Beverly Hills Rejuvenation FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4




